Related Experiment Video
Updated: Mar 28, 2026
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
A Comprehensive Review of the Revolutionary Potential of Blockchain in Safe, Secure, and Sustainable Pharmaceutical
Md Faiyazuddin1, Keshav Moharir2, Amol D Gholap3
1Centre for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India. md.faiyazuddin@gmail.com.
Background:
Pharmaceutical research and industrial operations generate vast volumes of sensitive data across drug discovery, formulation development, manufacturing, and distribution, necessitating secure, transparent, and reliable digital infrastructures. The global counterfeit drug market exceeds $200 billion annually, posing a significant threat to patient safety and public health. Blockchain Technology (BT) has demonstrated the potential to reduce counterfeit medicine circulation by approximately 40%, offering a transformative framework for pharmaceutical data governance.
Methods:
A systematic literature review was performed using ScienceDirect, PubMed, IEEE Xplore, and SpringerLink databases to analyze peer-reviewed studies published between January 2017 and December 2024. Structured keyword strategies and predefined inclusion and exclusion criteria were employed to evaluate blockchain-driven pharmaceutical operations and their integration with Artificial Intelligence (AI) and the Internet of Things (IoT).
Results:
The findings reveal that BT substantially improves data integrity, immutability, traceability, transparency, and security across pharmaceutical workflows. Integration with AI and IoT further enables real-time monitoring and predictive analytics, leading to 30-55% improvements in operational efficiency, 25-50% reductions in logistics and compliance-related costs, and significant enhancements in clinical trial data accuracy, pharmacovigilance reporting efficiency, intellectual property protection, and genomic data governance and counterfeit drug prevention.
Conclusion:
Blockchain-driven pharmaceutical ecosystems represent a paradigm shift in drug development, manufacturing, and distribution. Despite substantial benefits, challenges related to scalability, interoperability, data governance, and regulatory harmonization remain. Future research should prioritize the development of standardized frameworks, scalable architectures, and regulatory policies to accelerate industrial adoption and clinical translation.
More Related Videos
Related Concept Videos
01:29Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
01:28Biopharmaceutics and Pharmacokinetics: Overview
01:28Drug Products: Biologics, Biosimilars and Interchangeables
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...